- (PLX AI) - AstraZeneca entered into a new global development and commercialization agreement with Ionis Pharmaceuticals for eplontersen.
- • AstraZeneca says the liver-targeted antisense therapy is in Phase III development for the treatment of transthyretin amyloidosis
- • AstraZeneca will pay Ionis an upfront payment of $200m and additional conditional payments of up to $485m following regulatory approvals
- • It will also pay up to $2.9bn of sales-related milestones based on sales thresholds between $500m and $6bn, plus royalties in the range of low double-digit to mid-twenties percentage depending on the region
© 2021 PLX AI
